Manufacturer of the weight-loss drug Zepbound used in the agreement.

The drugmaker selling Zepbound directly through its LillyDirect platform.

Eli Lilly has launched a similar cash-pay program for their weight-loss drug Zepbound.

Eli Lilly also manufactures weight loss drugs that compete with MariTide.

Main rival of Novo Nordisk that also has a direct-to-consumer online pharmacy for its weight loss drugs.

Noted as a strong performer in the healthcare sector.

Announced plans to invest $27 billion in U.S. manufacturing due to demand for its products.

Eli Lilly plans to invest at least $27 billion in new manufacturing sites in the U.S. as demand for its drugs increases.

The company released higher doses of Zepbound in single-dose vials.

The stock gained more than 2% after launching new vials of its weight loss drug.

Eli Lilly's shares are up after announcing a price drop for Zepbound.

Shares rose 1% after launching higher dose vials of its weight loss drug Zepbound.